西妥昔单抗联合化疗在复发或转移头颈部鳞状细胞癌中的应用

Combined use of cetuximab and chemotherapy in recurrent or metastatic squamous cell carcinoma of head and neck

复发或转移头颈部鳞状细胞癌（SCCHN）预后较差.西妥昔单抗是一种可抑制表皮生长因子（EGFR）的单克隆抗体,并可提高包括顺铂在内的多种化疗药物疗效.多项临床研究结果显示,西妥昔单抗联合化疗对复发或转移头颈部鳞癌有效,以其高疗效和低不良反应在治疗中显示出了优势.

Recurrent or metastatic squamous cell carcinoma of the head and neck（SCCHN） has a poor prognosis. Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor （EGFR） and improves the effect of several chemotherapeutical agents including cisplatin. Several clinical trials have shown that cetuximab combined with chemotherapy was effective and well tolerated for the treatment of recurrent or metastatic SCCHN. The strengths of such treatment are its high efficacy and low toxicity.